| Autor: |
Aaqib M. Bhat, Bhopal C. Mohapatra, Haitao Luan, Insha Mushtaq, Sukanya Chakraborty, Samikshan Dutta, Matthew D. Storck, Jane L. Meza, Subodh Lele, Ming-Fong Lin, Leah M. Cook, Eva Corey, Colm Morrissey, Donald W. Coulter, M. Jordan Rowley, Kaustubh Datta, Vimla Band, Hamid Band |
| Rok vydání: |
2023 |
| Předmět: |
|
| Zdroj: |
bioRxiv |
| DOI: |
10.1101/2023.03.18.533299 |
| Popis: |
While better management of loco-regional prostate cancer (PC) has greatly improved survival, advanced PC remains a major cause of cancer deaths. Identification of novel, targetable, pathways that contribute to tumor progression of PC could open new therapeutic options. The di-ganglioside GD2 is a target of FDA-approved antibody therapies in neuroblastoma, but the role of GD2 in PC has been only little explored. Here, we show that GD2 is expressed on a small subpopulation of PC cells in a subset of patients, especially in metastatic PC. Variable levels of cell surface GD2 expression are seen in most PC cell lines, and the expression is highly upregulated by experimental induction of lineage progression or enzalutamide resistance in CRPC cell models. GD2highcell fraction is enriched upon growth of PC cells as tumorspheres and GD2highfraction is enriched in tumorsphere growth. CRISPR-Cas9 knockout (KO) of the rate-limiting GD2 biosynthetic enzyme GD3 Synthase (GD3S) in GD2-high CRPC cell models led to marked impairment of theirin vitrooncogenic traits, reduced cancer stem cell (CSC) and epithelial-mesenchymal transition (EMT) marker expression and growth as bone-implanted xenograft tumors. Our results support the potential role of GD3S and its product GD2 in promoting PC tumorigenesis by maintaining cancer stem cells and suggest the potential for GD2 targeting in advanced PC. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
